Jingyou Yu

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/2766196/jingyou-yu-publications-by-year.pdf
Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

71 papers	4,650 citations	23 h-index	68 g-index
78 ext. papers	7,444 ext. citations	22.4 avg, IF	5.6 L-index

#	Paper	IF	Citations
71	Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters.. *Npj Vaccines*, **2022**, 7, 2	9.5	0
70	Vaccines Elicit Highly Conserved Cellular Immunity to SARS-CoV-2 Omicron.. *Nature*, **2022**,	50.4	53
69	Vaccines Elicit Highly Cross-Reactive Cellular Immunity to the SARS-CoV-2 Omicron Variant. **2022**,		6
68	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. *Science Translational Medicine*, **2022**, 14,	17.5	6
67	A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques.. *Med*, **2022**,	31.7	1
66	Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques. **2022**,		2
65	Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice.. *Npj Vaccines*, **2022**, 7, 23	9.5	2
64	Characterization of immune responses in fully vaccinated individuals following breakthrough infection with the SARS-CoV-2 delta variant.. *Science Translational Medicine*, **2022**, eabn6150	17.5	12
63	SARS-CoV-2 receptor binding domain displayed on HBsAg virus-like particles elicits protective immunity in macaques.. *Science Advances*, **2022**, 8, eabl6015	14.3	3
62	Vaccine protection against the SARS-CoV-2 Omicron variant in macaques.. *Cell*, **2022**,	56.2	3
61	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques.. *Science Translational Medicine*, **2022**, eabm4996	17.5	1
60	Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants.. *New England Journal of Medicine*, **2022**,	59.2	35
59	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates.. *PLoS Biology*, **2022**, 20, e3001609	9.7	0
58	Reduced SARS-CoV-2 disease outcomes in Syrian hamsters receiving immune sera: Quantitative image analysis in pathologic assessments.. *Veterinary Pathology*, **2022**, 3009858221095794	2.8	0
57	Epidemiological and Immunological Features of Obesity and SARS-CoV-2. *Viruses*, **2021**, 13,	6.2	4
56	mRNA Vaccines Induce Rapid Antibody Responses in Mice **2021**,		2
55	COVID-19 mRNA Vaccine Immunogenicity in Immunosuppressed Individuals. *Journal of Infectious Diseases*, **2021**,	7	2

54	Optimization of Non-Coding Regions for a Non-Modified mRNA COVID-19 Vaccine. *Nature*, **2021**,	50.4	9
53	A Modular Biomaterial Scaffold-Based Vaccine Elicits Durable Adaptive Immunity to Subunit SARS-CoV-2 Antigens. *Advanced Healthcare Materials*, **2021**, 10, e2101370	10.1	2
52	Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines. *New England Journal of Medicine*, **2021**, 385, 2010-2012	59.2	57
51	SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques. *Nature Communications*, **2021**, 12, 5877	17.4	9
50	Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery Against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques. *Journal of Virology*, **2021**, JVI0159921	6.6	2
49	Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature*, **2021**, 590, 630-634	50.4	498
48	Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters **2021**,		10
47	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. *JAMA - Journal of the American Medical Association*, **2021**, 325, 1535-1544	27.4	139
46	Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays. *Journal of Virology*, **2021**,	6.6	40
45	Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques Following SARS-CoV-2 Vaccination and Infection. *Journal of Virology*, **2021**,	6.6	14
44	Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity **2021**,		6
43	Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques. *Nature*, **2021**, 596, 423-427	50.4	22
42	Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. *Nature*, **2021**, 596, 268-272	50.4	122
41	Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques. *Cell*, **2021**, 184, 3467-3473.e11	56.2	23
40	Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera. *Journal of Virology*, **2021**, 95, e0040421	6.6	14
39	Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. *JAMA - Journal of the American Medical Association*, **2021**, 325, 2370-2380	27.4	120
38	A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates **2021**,		3
37	Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19 **2021**,		10

36	Discrete SARS-CoV-2 antibody titers track with functional humoral stability. *Nature Communications*, **2021**, 12, 1018	17.4	46
35	Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2. *JCI Insight*, **2021**, 6,	9.9	11
34	Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern. *Science Translational Medicine*, **2021**, 13, eabj3789	17.5	13
33	SERINC proteins potentiate antiviral type I IFN production and proinflammatory signaling pathways. *Science Signaling*, **2021**, 14, eabc7611	8.8	4
32	Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants. *Science Translational Medicine*, **2021**, 13, eabj2641	17.5	8
31	Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination. *New England Journal of Medicine*, **2021**, 385, 951-953	59.2	77
30	Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. *Journal of Virology*, **2021**, 95, e0097421	6.6	3
29	Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	13
28	Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques **2021**,		8
27	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor-binding domain vaccine in aged mice. *Science Translational Medicine*, **2021**, eabj5305	17.5	2
26	Phosphate-mediated coanchoring of RBD immunogens and molecular adjuvants to alum potentiates humoral immunity against SARS-CoV-2. *Science Advances*, **2021**, 7, eabj6538	14.3	3
25	Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality. *Cell*, **2020**, 183, 1508-1519.e12	38.6	134
24	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. *Science*, **2020**, 369, 812-817	33.3	592
23	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science*, **2020**, 369, 806-811	33.3	748
22	Protective efficacy of an attenuated Mtb ΔprgG vaccine in mice. *PLoS Pathogens*, **2020**, 16, e1009096	7.6	7
21	Dynamics and significance of the antibody response to SARS-CoV-2 infection **2020**,		60
20	Epidemiological and immunological features of obesity and SARS-CoV-2 **2020**,		3
19	T cell and antibody functional correlates of severe COVID-19 **2020**,		6

18	Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. *Science Immunology*, **2020**, 5,	28	353
17	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. *Nature*, **2020**, 586, 583-588	50.4	550
16	Approaches and Challenges in SARS-CoV-2 Vaccine Development. *Cell Host and Microbe*, **2020**, 28, 364-370	29.4	64
15	Distinct Early Serological Signatures Track with SARS-CoV-2 Survival. *Immunity*, **2020**, 53, 524-532.e4	32.3	219
14	Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. *Nature Medicine*, **2020**, 26, 1694-1700	50.5	176
13	CD4-Dependent Modulation of HIV-1 Entry by LY6E. *Journal of Virology*, **2019**, 93,	6.6	13
12	TIM-mediated inhibition of HIV-1 release is antagonized by Nef but potentiated by SERINC proteins. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 5705-5714	11.5	20
11	Emerging Role of LY6E in Virus-Host Interactions. *Viruses*, **2019**, 11,	6.2	22
10	Relating GPI-Anchored Ly6 Proteins uPAR and CD59 to Viral Infection. *Viruses*, **2019**, 11,	6.2	6
9	The Inhibition of HIV-1 Entry Imposed by Interferon Inducible Transmembrane Proteins Is Independent of Co-Receptor Usage. *Viruses*, **2018**, 10,	6.2	9
8	The V3 Loop of HIV-1 Env Determines Viral Susceptibility to IFITM3 Impairment of Viral Infectivity. *Journal of Virology*, **2017**, 91,	6.6	32
7	Interferon-inducible LY6E Protein Promotes HIV-1 Infection. *Journal of Biological Chemistry*, **2017**, 292, 4674-4685	5.4	29
6	Nonhuman Primate IFITM Proteins Are Potent Inhibitors of HIV and SIV. *PLoS ONE*, **2016**, 11, e0156739	3.7	18
5	IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein. *Cell Reports*, **2015**, 13, 145-156	10.6	109
4	Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman Primates		4
3	An adjuvanted SARS-CoV-2 RBD nanoparticle elicits neutralizing antibodies and fully protective immunity in aged mice		1
2	SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaques		2
1	Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. *New England Journal of Medicine*,	59.2	45